Guerbet Reports Q1 2026 Revenue Up 2.6% at Constant Exchange Rates

Guerbet, a global specialist in contrast agents and solutions for medical imaging, reported its first-quarter 2026 revenue increased by 2.6% at constant exchange rates (CER) and on a like-for-like basis, reaching €177.4 million. However, reported revenue saw a 1.5% decrease compared to the first quarter of 2025, largely due to a negative foreign exchange impact of €7.2 million, primarily from the depreciation of the US dollar and certain Asian currencies. The results also incorporated the anticipated negative impact from operational issues at the Raleigh site in North Carolina.

The EMEA region remained a growth driver, with revenue up 4.5% at CER, benefiting from improved activity in France following supply reform impacts in the prior year. Asia also contributed positively with a 6.0% increase at CER. Conversely, the Americas region experienced a 3.0% decline at CER, driven by decreased volumes in North America linked to the ongoing remediation at the Raleigh manufacturing facility. The company expects a steady improvement in batch release rates from Raleigh.

Within its business segments, Diagnostic Imaging saw a 1.9% rise at CER. Magnetic Resonance Imaging (MRI) grew by 4.4% at CER, supported by the geographic expansion of its Elucirem product. X-ray revenue saw a modest 0.4% increase. Interventional Radiology showed strong momentum, with revenue up 7.8% at CER, driven by Lipiodol sales.

Guerbet stated that the remediation plan at the Raleigh site, initiated in late 2025 to address FDA requests, is progressing as expected. The company also began a consultation process with France's Economic and Social Committee regarding a redundancy plan as part of its group transformation efforts. Full financial targets for 2026 are expected to be communicated by July 23.